RxDoctor Payments Data

Brent Wilson, MD

Emergency Medical Services · Oklahoma City, OKNPI 1760440879

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 24 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by Inari Medical, Inc. at 33.9% of the total. Reporting peaked in 2024 at $303 and has fallen 74.9% since, to $76 in 2025.

$565in general payments, 2019–2025

Across 24 payments — averaging $23.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inari Medical, Inc.$192
  • Johnson & Johnson$143
  • Pfizer$130
  • E.r. Squibb & Sons, L.L.C.$43
  • Novo Nordisk$35
  • Melinta Therapeutics, LLC$23

What the payments were for

  • Food & beverage$565100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$565 in reported general payments places this provider in the 80th percentile of 58 emergency medical services providers in Oklahoma.

See all emergency medical services providers in Oklahoma

Medicare billing

Part B allowed, 2024
$158,853
Medicare patients
950
Services billed
1,065

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban14$10,093
Cefdinir51$1,155
Naloxone Hcl12$696
Memantine Hcl22$664
Ondansetron OdtOndansetron64$649
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen83$545
Mirtazapine23$365
Sertraline Hcl15$308
Donepezil Hcl15$296
Tizanidine Hcl57$278
Clindamycin Hcl13$197
Amlodipine Besylate17$183
Levothyroxine Sodium23$167
Ciprofloxacin Hcl15$153
Methylprednisolone20$141

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$130$10,09314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 58 emergency medical services providers in Oklahoma.

Other emergency medical services in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →